On the morning of June 29, "The Lancet-Infectious Diseases" published online the world's first clinical safety and immunogenicity data on the inactivated new crown vaccine for people aged 3-17 years
The results of the study showed that the immune response of children and adolescents was better than that of adults aged 18-59 and those aged 60 and over following the same immunization schedule with two doses of the medium-dose vaccine
The author of the above study is Gao Qiang, general manager of Beijing Kexing Zhongwei, and others.
At present, China has approved the emergency use of the inactivated new crown vaccine developed by the Beijing Research Institute of Sinopharm Zhongsheng and Beijing Kexing Zhongwei Company in the 3-17 age group
The study is a clinical trial conducted in healthy children and adolescents aged 3-17 years in Zanhuang County, Hebei Province, China
According to the study, from October 31 to December 2, 2020, 72 subjects were included in the phase I clinical study; from December 12 to December 30, 2020, 480 subjects were included in the phase II clinical study Clinical research
The safety results of the paper showed that among 550 subjects who received at least one dose of test vaccine or control, the incidence of adverse reactions in the 1.
The immunogenicity results of the thesis showed that 100% of the subjects in the 1.
The study pointed out that the immune response of children and adolescents was higher than the results of the study 28 days after 18-59-year-old adults and 60-year-olds and older people received two doses of 3ug vaccine following the same immunization schedule (GMT 44 and 42 respectively)
Further analysis of age groups showed that there was no significant difference in immune response between different ages
Based on the above results, the author suggests that children and adolescents aged 3-17 years will use the vaccine at a dose of 3 µg in future studies
The study also has some limitations
Focus on the new crown pneumonia epidemic
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
